This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ullian, M. E. Articles by Egan, B. M. Search for Related Content PubMed PubMed Citation Articles by Ullian, M. E. Articles by Egan, B. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PHENYLEPHRINE

(Hypertension. 1996;27:1346-1352.)
© 1996 American Heart Association, Inc.

Articles

Carbenoxolone Damages Endothelium and Enhances Vasoconstrictor Action in Aortic Rings

Michael E. Ullian; Debra J. Hazen-Martin; Lyle G. Walsh; Rajesh K. Davda; Brent M. Egan

From the Departments of Medicine (M.E.U., L.G.W., R.K.D., B.M.E.), Pathology (D.J.H.-M.), and Pharmacology (B.M.E.), Medical University of South Carolina and Ralph H. Johnson Veterans Administration Hospital, Charleston.

Abstract Carbenoxolone causes hypertension indirectly by inhibition of 11ß-hydroxysteroid dehydrogenase and consequent elevation of intracellular glucocorticoid levels and enhancement of vasoconstrictor action. We performed the present study to determine whether carbenoxolone also enhances vascular tone directly by mechanisms independent of glucocorticoids and other systemic influences. Exposure of rat aortic rings to 10 to 100 µmol/L carbenoxolone in aerated Krebs-Henseleit buffer for 24 hours resulted in concentration-dependent increases in angiotensin II (Ang II) (100 nmol/L)–stimulated contractions and significant shifting of the phenylephrine cumulative contraction curve to the left but not increases in KCl (120 mmol/L)–stimulated contractions. Maximal enhancement of Ang II contraction was 39%. In contrast, brief (15-minute) exposure to 100 µmol/L carbenoxolone did not alter Ang II contractions. Mechanical denudation of the endothelium obviated enhancement of Ang II contractions by carbenoxolone, suggesting interaction of carbenoxolone with the endothelium. Endothelium-dependent relaxation of precontracted rings to acetylcholine or ATP was reduced by more than 90% by 24-hour pretreatment with 100 µmol/L carbenoxolone but not with 100 µmol/L deoxycorticosterone acetate (a mineralocorticoid) or 100 µmol/L glycyrrhizic acid (a natural 11ß-hydroxysteroid dehydrogenase inhibitor). Vascular smooth muscle relaxation with sodium nitroprusside was not inhibited by carbenoxolone. Incubation of cultured endothelial cells with 100 µmol/L carbenoxolone for 24 hours did not inhibit nitric oxide synthase activity, as measured by conversion of [³H]L-arginine to [³H]L-citrulline. Electron micrography demonstrated that endothelial cell ultrastructure but not vascular smooth muscle cell ultrastructure was abnormal after incubation of rings for 24 hours with 100 µmol/L carbenoxolone. These studies suggest that carbenoxolone concentrations higher than 10 µmol/L enhance vasoconstrictor action via selective toxicity to the endothelium and elimination of endothelium-dependent relaxation.

Key Words: carbenoxolone • endothelium • muscle, smooth, vascular • vasoconstriction • receptors, adrenergic • angiotensin II

This article has been cited by other articles:

				V. M. Vehaskari and L. L. Woods Prenatal Programming of Hypertension: Lessons from Experimental Models J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2545 - 2556. [Full Text] [PDF]

				J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response Endocr. Rev., October 1, 2004; 25(5): 831 - 866. [Abstract] [Full Text] [PDF]

				J. R. de Groot, T. Veenstra, A. O. Verkerk, R. Wilders, J. P.P. Smits, F. J.G. Wilms-Schopman, R. F. Wiegerinck, J. Bourier, C. N.W. Belterman, R. Coronel, et al. Conduction slowing by the gap junctional uncoupler carbenoxolone Cardiovasc Res, November 1, 2003; 60(2): 288 - 297. [Abstract] [Full Text] [PDF]

				M. DODIC, V. HANTZIS, J. DUNCAN, S. REES, I. KOUKOULAS, K. JOHNSON, E. M. WINTOUR, and K. MORITZ Programming effects of short prenatal exposure to cortisol FASEB J, July 1, 2002; 16(9): 1017 - 1026. [Abstract] [Full Text] [PDF]

				P. W.F. Hadoke, C. Christy, Y. V. Kotelevtsev, B. C. Williams, C. J. Kenyon, J. R. Seckl, J. J. Mullins, and B. R. Walker Endothelial Cell Dysfunction in Mice After Transgenic Knockout of Type 2, but Not Type 1, 11{beta}-Hydroxysteroid Dehydrogenase Circulation, December 4, 2001; 104(23): 2832 - 2837. [Abstract] [Full Text] [PDF]

				E. P. Gomez-Sanchez and C. E. Gomez-Sanchez Maternal Hypertension and Progeny Blood Pressure : Role of Aldosterone and 11ß-HSD Hypertension, June 1, 1999; 33(6): 1369 - 1373. [Abstract] [Full Text] [PDF]